Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai

XI'AN, China, March 3, 2011 /PRNewswire-Asia/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTCQB: HFGB) ("Huifeng" or the "Company"), a leading developer and producer of plant extracts and biochemical raw materials used in pharmaceuticals, nutraceuticals and food production, announced today that the Company will present at the upcoming 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai being held March 6th through March 8th, 2011, at Le Royal Meridien Shanghai Hotel in China.  

The date, time and location of Huifeng's presentation at the conference are as follows:

The 2011 Rodman & Renshaw Annual China Investment Conference is a three day event that will feature presentations from CEOs and CFOs of more than 150 companies from China representing industries including Agriculture, Auto, Cleantech & Energy, Consumer/Retail, Education, Healthcare, Industrial, Metals & Mining and Technology. It is expected that there will be more than 1,000 registered attendees at this invitation only event, which will include numerous networking opportunities, corporate presentations, Q&A sessions and one-on-one meetings throughout the day.

Huifeng management will be hosting one-on-one meetings with investors by request throughout the conference to provide an overview of its business. For more information about the conference, please contact Rodman & Renshaw representative - Lily Khaykina at [email protected], or to register please visit http://ww.rodm.com/conferences.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB: HFGB), located in Xi'an, People's Republic of China (PRC), develops and supplies high quality plant extracts and raw materials used in the production of pharmaceuticals, nutraceuticals and food. Founded in 2000, the Company is the leading Chinese producer and exporter of Rutin and Rutin-related plant derived flavonoids, as well as a significant producer of Diosmin, both of which have powerful antioxidant and medicinal properties and are used as ingredients in therapies that target venous diseases, inflammation, and dermatitis among other chronic health issues. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. For more information about Huifeng Bio-Pharmaceutical Technology, please visit its corporate website at: http://www.hfgb.cn/

To be added to the Company's email distribution for future news releases, please send your request to [email protected]

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance and efficacy of existing and new products, and other factors disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31, 2009 and all of the Company's subsequent Quarterly Reports on Form 10Q, especially in the "Risk Factors" sections of these reports. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED